330 related articles for article (PubMed ID: 28058097)
1. Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights.
Shahrabi S; Khosravi A; Shahjahani M; Rahim F; Saki N
Oncol Rev; 2016 Oct; 10(2):311. PubMed ID: 28058097
[TBL] [Abstract][Full Text] [Related]
2. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
[TBL] [Abstract][Full Text] [Related]
4. Myelodysplastic syndromes: Contemporary review and how we treat.
Gangat N; Patnaik MM; Tefferi A
Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
[TBL] [Abstract][Full Text] [Related]
5. Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.
Wu L; Song L; Xu L; Chang C; Xu F; Wu D; He Q; Su J; Zhou L; Xiao C; Zhang Z; Zhao Y; Chen S; Li X
Tumour Biol; 2016 Apr; 37(4):4633-40. PubMed ID: 26508027
[TBL] [Abstract][Full Text] [Related]
6. The molecular pathogenesis of the myelodysplastic syndromes.
Pellagatti A; Boultwood J
Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
[TBL] [Abstract][Full Text] [Related]
7. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
Itzykson R; Kosmider O; Fenaux P
Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
[TBL] [Abstract][Full Text] [Related]
8. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
9. The Genetics of Myelodysplastic Syndromes: Clinical Relevance.
Chiereghin C; Travaglino E; Zampini M; Saba E; Saitta C; Riva E; Bersanelli M; Della Porta MG
Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440317
[TBL] [Abstract][Full Text] [Related]
10. Genetic abnormalities and pathophysiology of MDS.
Hosono N
Int J Clin Oncol; 2019 Aug; 24(8):885-892. PubMed ID: 31093808
[TBL] [Abstract][Full Text] [Related]
11. Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution.
Bravo GM; Lee E; Merchan B; Kantarjian HM; García-Manero G
Br J Haematol; 2014 Sep; 166(5):646-59. PubMed ID: 24903747
[TBL] [Abstract][Full Text] [Related]
12. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
Thol F; Kade S; Schlarmann C; Löffeld P; Morgan M; Krauter J; Wlodarski MW; Kölking B; Wichmann M; Görlich K; Göhring G; Bug G; Ottmann O; Niemeyer CM; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
Blood; 2012 Apr; 119(15):3578-84. PubMed ID: 22389253
[TBL] [Abstract][Full Text] [Related]
13. Impact of single versus multiple spliceosome mutations on myelodysplastic syndrome.
Nagehan P; Sabbir M; Song J; Mohammad H
J Clin Exp Hematop; 2023; 63(3):173-176. PubMed ID: 37766563
[TBL] [Abstract][Full Text] [Related]
14. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.
Chen Z; Wang SA; Goswami M; Tang G; Routbort MJ; Patel KP; Luthra R; Medeiros LJ; Ok CY
Leuk Res; 2019 Nov; 86():106227. PubMed ID: 31557598
[TBL] [Abstract][Full Text] [Related]
15. Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromes.
Lee WH; Lin CC; Wang YH; Yao CY; Kuo YY; Tseng MH; Peng YL; Hsu CA; Sun HI; Chuang YK; Hsu CL; Tien FM; Tsai CH; Chou WC; Hou HA; Tien HF
Hematol Oncol; 2023 Aug; 41(3):463-473. PubMed ID: 36420747
[TBL] [Abstract][Full Text] [Related]
16. [Current diagnosis and treatment for myelodysplastc syndromes].
Hata T
Rinsho Ketsueki; 2017; 58(4):373-380. PubMed ID: 28484169
[TBL] [Abstract][Full Text] [Related]
17. [Mutational analysis of RNA splicing machinery genes SF3B1, U2AF1 and SRSF2 in 118 patients with myelodysplastic syndromes and related diseases].
Wang JY; Ma J; Lin YN; Wang J; Shen H; Gui FM; Han C; Li QH; Song Z; Wang XJ
Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):192-197. PubMed ID: 28395441
[No Abstract] [Full Text] [Related]
18. Association of Somatic Gene Mutations with Risk of Transformation into Acute Myeloid Leukemia in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis.
Sutandyo N; Mulyasari R; Kosasih A; Rinaldi I; Louisa M; Kevinsyah AP; Winston K
Asian Pac J Cancer Prev; 2022 Apr; 23(4):1107-1116. PubMed ID: 35485665
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes.
Cedena MT; Rapado I; Santos-Lozano A; Ayala R; Onecha E; Abaigar M; Such E; Ramos F; Cervera J; Díez-Campelo M; Sanz G; Rivas JH; Lucía A; Martínez-López J
Oncotarget; 2017 Dec; 8(63):106948-106961. PubMed ID: 29291002
[TBL] [Abstract][Full Text] [Related]
20. [Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts].
Cai YN; Xu ZF; Li B; Qin TJ; Pan LJ; Qu SQ; Hu NB; Liu D; Huang HJ; Shi ZX; Zhang YD; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):379-386. PubMed ID: 32536134
[No Abstract] [Full Text] [Related]
[Next] [New Search]
